You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of CaSR nutrient therapy for childhood diarrhea

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract Acute infectious diarrhea is a worldwide problem especially among infants young children and immune compromised patients Sadly million children die each year not because of the infections causing diarrhea but due to the associated dehydration The pro absorptive Oral Rehydration Solution ORS is the only recommended oral therapy for children with acute diarrhea yet it ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Pyruvate dehydrogenase complexPDCdeficiencyPDCDis a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncatedTreatment of PDCD remains a seriousunmetchallengeThere has never been a controlled trial of any intervention for PDCDthusthere is no proven therapy for affected patientsDichloroacetateDCArepresents the first targeted therapy for ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Probiotic Platform to Treat Necrotizing Enterocolitis

    SBC: MONON BIOVENTURES LLC            Topic: 300

    PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Develop a new cisplatin based drug combination with reduced ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a Nutraceutical Product against Noise Induce Hearing Loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Fibrin Specific Nuclear Probe to Reduce LVAD Adverse Events

    SBC: CAPELLA IMAGING, LLC            Topic: NHLBI

    Despite the myriad major advances in cardiology the prognosis for patients with severe medically refractive heart failure HF is exceedingly poor Approximately deaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizations At least of these deaths were directl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government